Imaging agents for Alzheimer's move closer to market after positive trials
This article was originally published in Clinica
Executive Summary
Avid Radiopharmaceuticals' PET imaging agent, florbetapir F18, could help diagnose Alzheimer's disease earlier, a phase III trial has suggested.